Archives
-
2,2,2-Trichloroethanol for Protein Workflows
2026-08-24
Use 2,2,2-Trichloroethanol as a flexible protein visualization and quality-control reagent for electrophoresis, differentiation studies, and signaling assays. This workflow-focused guide connects gel-based protein readouts with the multimodal maturation strategy reported in a Parkinson’s disease cell-therapy model.
-
LAMP1, CXCR3, and Macrophage Polarization
2026-08-24
The 2024 International Immunopharmacology study identifies LAMP1-dependent autophagy as a context-sensitive regulator of CXCL10–CXCR3-driven macrophage polarization. Its key finding is that CXCL10 and CXCR3 antagonism can produce opposite polarization outcomes in non-inflammatory versus poly(I:C)-stimulated macrophages, with AMG 487 also reducing acute lung injury in a mouse model.
-
Dynasore A1605 for Reliable Cell Assays
2026-08-23
Learn how Dynasore (SKU A1605) can help researchers separate dynamin-dependent trafficking effects from nonspecific changes in cell viability, proliferation, or cytotoxicity assays. This scenario-based guide covers mechanism, stock preparation, controls, interpretation, and practical product selection using literature-linked evidence.
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer
2026-08-22
The reference study develops a localized tumor-suppressor replacement strategy using chemically modified p21 mRNA encapsulated in lipid nanoparticles for intravesical treatment of bladder cancer. Its data connect bladder-localized expression with cell-cycle inhibition, DNA-damage signaling, apoptosis, and tumor suppression in an orthotopic mouse model, while also highlighting the translational questions that remain before clinical application.
-
PP 2 (AG 1879) in Src–Cytoskeleton Research
2026-08-22
PP 2 (AG 1879) is a selective Src-family kinase probe for dissecting signaling beyond proliferation assays. This guide connects its Lck and Fyn activity to PA–Src–FAK–RhoA/ROCK control of cytoskeletal remodeling and provides a rigorous assay framework.
-
CUDC-907: Practical PI3K/HDAC Workflow Guide
2026-08-21
CUDC-907 is a dual PI3K and HDAC inhibitor for controlled cell-based studies that examine simultaneous signaling and chromatin-related responses. This dossier-led guide covers preparation, exposure, pathway readouts, apoptosis assay design, and limitations; the compound is for scientific research only and not for diagnostic, therapeutic, or clinical use.
-
Patient-Derived Gastric Cancer Assembloids and Drug Response
2026-08-20
The 2025 study developed patient-derived gastric cancer assembloids by combining matched tumor organoids with tumor-associated stromal cell subpopulations. Compared with organoid monocultures, these models altered inflammatory, extracellular-matrix, and tumor-progression programs and revealed drug responses that depended on both patient and stromal context.
-
RNA Pol II Inhibition and Active Cell Death Signaling
2026-08-20
Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic response to depletion of hypophosphorylated RNA Pol IIA, rather than through transcriptional collapse alone. The study identifies a Pol II degradation-dependent apoptotic response and provides a framework for interpreting the cytotoxicity of transcription-targeting and other anticancer compounds.
-
Tioconazole Workflows for Antifungal Research
2026-08-19
Build more reproducible antifungal screens with Tioconazole by controlling solubility, solvent exposure, assay timing, and orthogonal mechanism readouts. This workflow also explains how metabolic-state insights from leukemia research can improve experimental design without overstating cross-domain evidence.
-
Fasudil (HA-1077) HCl: Assay Logic
2026-08-19
Fasudil (HA-1077) HCl is a ROCK inhibitor for dissecting cytoskeletal signaling, proliferation, migration, and apoptosis. This guide develops an assay-centered framework that connects ROCK perturbation with Hippo-pathway readouts while clearly separating established evidence from testable hypotheses.
-
CPI-613 and the Mitochondrial Ferroptosis Frontier
2026-08-18
CPI-613 offers translational researchers a mechanism-linked way to perturb mitochondrial carbon metabolism while exploring how metabolic stress intersects with apoptosis and ferroptosis. This article connects PDH and KGDH inhibition with mitochondrial calcium signaling, outlines validation strategies, and defines the evidence boundaries for advancing CPI-613 studies in AML, NSCLC, and other tumor models.
-
2D and 3D Radiosensitizer Screening in Lung Cancer
2026-08-18
The 2025 Acta Oncologica study systematically compared DNA-PKcs, ATR, PARP, and IAP pathway inhibitors in matched 2D and 3D lung cancer models. Its results show that 2D assays often identify the same strong radiosensitizers as 3D systems, while extracellular-matrix cultures can reveal additional context-dependent responses that improve preclinical prioritization.
-
SIS3: A Mechanistic Guide to Smad3 Assays
2026-08-17
SIS3 is a selective Smad3 inhibitor for resolving TGF-β pathway biology in fibrosis, renal, and cartilage models. This guide uses osteoarthritis evidence to show how assay design can distinguish pathway inhibition from downstream matrix effects.
-
PKM2 Inhibition: From Glycolysis to Translation
2026-08-17
PKM2 inhibitor (compound 3k) offers a mechanistically grounded route to interrogate cancer metabolism, tumor cell selectivity, and immune metabolic reprogramming. This thought-leadership analysis connects its preclinical oncology profile with USP7–PKM2 findings in severe acute pancreatitis and outlines a biomarker-led translational strategy.
-
Amphotericin B Workflows for Biofilm Research
2026-08-16
Build more informative Candida biofilm assays with Amphotericin B, from sterol-dependent membrane disruption to PP2A–autophagy-associated drug resistance. This workflow also shows how to separate direct antifungal activity from solvent effects, biofilm tolerance, and immune-cell toxicity.